Sign Up to like & get
recommendations!
1
Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.08.042
Abstract: OBJECTIVE To assess pregnancy outcomes after exposure to AS04-HPV-16/18 vaccine (Cervarix, GSK, Belgium) prior to, or during pregnancy, as reported to a pregnancy registry. METHODS A pregnancy exposure registry was established to collect data in…
read more here.
Keywords:
as04 hpv;
hpv vaccine;
pregnancy;
pregnancy registry ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Expert Review of Vaccines"
DOI: 10.1080/14760584.2022.2021077
Abstract: ABSTRACT Background Cervical cancer is the third most frequent cancer in Chinese women aged 15–44 years old. Human papillomavirus (HPV) is recognized as the main etiologic agent of cervical carcinomas. This study aims to better…
read more here.
Keywords:
study;
hpv;
as04 hpv;
progression ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Asia-Pacific journal of clinical oncology"
DOI: 10.1111/ajco.13833
Abstract: INTRODUCTION The pivotal efficacy study assessed efficacy and safety of GSK's AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years up to 6 years. The present extension study, performed 4 years later, offered AS04-HPV-16/18 vaccination to…
read more here.
Keywords:
hpv vaccine;
year;
safety;
as04 hpv ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Singapore medical journal"
DOI: 10.11622/smedj.2017085
Abstract: INTRODUCTION Cervical cancer is the tenth most common cancer and the eighth most frequent cause of death among women in Singapore. As human papillomavirus (HPV) infection is the necessary cause of cervical cancer, the risk…
read more here.
Keywords:
as04 hpv;
cost effectiveness;
cost;
cervical cancer ... See more keywords